Based on the BEACON CRC trial, the combination of the anti‐EGFR antibody cetuximab and the BRAF inhibitor encorafenib is now approved in BRAF mutated mCRC after progressing on first‐line chemotherapy. Here, BRAF is linked to colorectal carcinoma.